TEXT
Disease site: Breast Cancer
Treatment Modality: Hormone Therapy
Status: In active follow-up
Patients are randomised to one of two treatment arms:
- Tamoxifen plus Triptorelin
- Exemestane plus Triptorelin
The aim of the trial is to evaluate the worth of ovarian function suppression (achieved by long-term use of Triptorelin) plus exemestane compared with Triptorelin plus tamoxifen, in premenopausal women with steroid hormone receptor positive early invasive breast cancer. The trial will recruit 1845 patients.
TEXT is one of three complementary trials (the STP Trials) coordinated by the IBCSG. These trials opened to recruitment internationally on the 4th August 2003. The trial is not yet open to recruitment in the UK. ICR-CTSU is acting as the UK spoke trials unit.
UK Chief Investigator: Dr H. Earl, University of Cambridge.
Sponsor: International Breast Cancer Study Group (IBCSG)
Berne, Switzerland
In the Clinical Trials Section
